Highlights from the Innovations in Cardiovascular Interventions Meeting: in favor of creativity and ingenuity

References

• Raval NY, Squara P, Cleman M, Yalamanchili K, Winklmaier M, Burkhoff D. Multicenter evaluation of noninvasive cardiac output measurement by bioreactance technique. J. Clin. Monit. Comput.22, 113–119 (2008).
   PubMedGoogle Scholar
• Leitman M, Sucher E, Kaluski E et al. Non-invasive measurement of cardiac output by whole-body bio-impedance during dobutamine stress echocardiography: clinical implications in patients with left ventricular dysfunction and ischaemia. Eur. J. Heart Fail.8, 136–140 (2006).
   PubMedGoogle Scholar
• Schwartz PJ, De Ferrari GM, Sanzo A et al. Long term vagal stimulation in patients with advanced heart failure: first experience in man. Eur. J. Heart Fail.10, 884–891 (2008).
   PubMed Web of Science ®Google Scholar
• Rittger H, Schertel B, Schmidt M, Justiz J, Brachmann J, Sinha AM. Three-dimensional reconstruction allows accurate quantification and length measurements of coronary artery stenoses. EuroIntervention5, 127–132 (2009).
   PubMedGoogle Scholar
• Topaz O. LightWire guidewire – the promise and outlook. Catheter Cardiovasc. Interv.70, 552–553 (2007).
   PubMedGoogle Scholar
• Segev A, Nili N, Qiang B et al. Human-grade purified collagenase for the treatment of experimental arterial chronic total occlusion. Cardiovasc. Revasc. Med.6, 65–69 (2005).
   PubMedGoogle Scholar
• Stone GW, Midei M, Newman W et al.; SPIRIT III Investigators. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA299, 1903–1913 (2008).
   PubMed Web of Science ®Google Scholar
• Stone GW, Midei M, Newman W et al.; SPIRIT III Investigators. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial. Circulation119, 680–686 (2009).
   PubMed Web of Science ®Google Scholar
• Nikolsky E, Lansky AJ, Sudhir K et al. SPIRIT IV trial design: a large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease. Am. Heart J.158, 520–526.e2 (2009).
   PubMed Web of Science ®Google Scholar
• Meredith IT, Worthley S, Whitbourn R et al. The next-generation Endeavor Resolute stent: 4-month clinical and angiographic results from the Endeavor Resolute first-in-man trial. EuroIntervention3, 50–53 (2007).
   PubMedGoogle Scholar
• Windecker S, Serruys PW, Wandel S et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet372(9644), 1163–1173 (2008).
   PubMed Web of Science ®Google Scholar
• Turco MA, Ormiston JA, Popma JJ et al. Polymer-based, paclitaxel-eluting TAXUS Liberté stent in de novo lesions: the pivotal TAXUS ATLAS trial. J. Am. Coll. Cardiol.49, 1676–1683 (2007).
   PubMedGoogle Scholar
• Nakazawa G, Granada JF, Alviar CL et al. Anti-CD34 antibodies immobilized on the surface of sirolimus-eluting stents enhance stent endothelialization. JACC Cardiovasc. Interv.3, 68–75 (2010).
   PubMed Web of Science ®Google Scholar
• Chevalier B, Silber S, Park SJ et al.; NOBORI 1 clinical investigators. Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberté paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial – Phase 2. Circ. Cardiovasc. Interv.2, 188–195 (2009).
   PubMed Web of Science ®Google Scholar
• Costa JR Jr, Abizaid A, Costa R et al. Preliminary results of the hydroxyapatite nonpolymer-based sirolimus-eluting stent for the treatment of single de novo coronary lesions a first-in-human analysis of a third-generation drug-eluting stent system. JACC Cardiovasc. Interv.1, 545–551 (2008).
   PubMedGoogle Scholar
• Waksman R, Erbel R, Di Mario C et al.; PROGRESS-AMS (Clinical Performance Angiographic Results of Coronary Stenting with Absorbable Metal Stents) Investigators. Early- and long-term intravascular ultrasound and angiographic findings after bioabsorbable magnesium stent implantation in human coronary arteries. JACC Cardiovasc. Interv.2, 312–320 (2009).
   PubMed Web of Science ®Google Scholar
• Ormiston JA, Serruys PW, Regar E et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet371(9616), 899–907 (2008).
   PubMed Web of Science ®Google Scholar
• Ramcharitar S, Gonzalo N, van Geuns RJ et al. First case of stenting of a vulnerable plaque in the SECRITT I trial-the dawn of a new era? Nat. Rev. Cardiol.6, 374–378 (2009).
   PubMedGoogle Scholar
• Granada JF, Pomeranz M, Heringes J, Odess I. vProtect luminal shield system. EuroIntervention3, 416–419 (2007).
   PubMedGoogle Scholar
• Capodanno D, Tamburino C. Properties and clinical development of a novel coating technology: the poly[bis(trifluoroethoxy)phosphazene]. Recent. Pat. Drug Deliv. Formul.4, 18–22 (2010).
   PubMedGoogle Scholar
• Karjalainen PP, Ylitalo AS, Juhani Airaksinen KE. Real world experience with the TITAN® stent: a 9-month follow-up report from the Titan PORI Registry. EuroIntervention2, 187–191 (2006).
   PubMedGoogle Scholar
• Piscione F, Danzi GB, Cassese S et al. Multicentre experience with MGuard net protective stent in ST-elevation myocardial infarction: safety, feasibility, and impact on myocardial reperfusion. Catheter Cardiovasc. Interv. (2009) (Epub ahead of print).
   PubMedGoogle Scholar
• Scheller B, Hehrlein C, Bocksch W et al. Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. Clin. Res. Cardiol.97, 773–781 (2008).
   PubMed Web of Science ®Google Scholar